Similar articles

• [Biological monitoring of oral estroprogestagen contraception].

  ANAES Agence nationale d'accréditation et d'evaluation en santé. ANAES Agence nationale d'accréditation et d'evaluation en santé. Gynecol Obstet Fertil. 2001 Mar;29(3):254-6. doi: 10.1016/s1297-9589(00)00071-0. Gynecol Obstet Fertil. 2001. PMID: 11305289 Review. French. No abstract available.
• Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.

  Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Jick H, et al. Lancet. 1995 Dec 16;346(8990):1589-93. doi: 10.1016/s0140-6736(95)91928-7. Lancet. 1995. PMID: 7500750
• Cardiovascular disease and oral contraceptive use.

  Bromham DR, Skouby SO. Bromham DR, et al. Eur J Contracept Reprod Health Care. 1996 Mar-May;1(1):1-2. doi: 10.3109/13625189609150649. Eur J Contracept Reprod Health Care. 1996. PMID: 9678131 Review. No abstract available.
• Does the type of progestin influence the production of clotting factors?

  Stanczyk FZ, Mathews BW, Cortessis VK. Stanczyk FZ, et al. Contraception. 2017 Feb;95(2):113-116. doi: 10.1016/j.contraception.2016.07.007. Epub 2016 Jul 13. Contraception. 2017. PMID: 27421764 No abstract available.
• [Venous pathology with estrogens-progestagens].

  Vin F, Allaert FA, Levardon M. Vin F, et al. Phlebologie. 1989 Jul-Oct;42(3):473-9; discussion 479-80. Phlebologie. 1989. PMID: 2626469 French. No abstract available.